Q-Med's Durolane Knee Therapy Not Approvable - FDA Panel

By Health News Daily / Health News Daily Aug. 20, 2009
More Stories / Word Count: 625 / Article # 090820g1

Executive Summary

Q-Med's Durolane hyaluronic acid treatment is not approvable for treatment of knee osteoarthritis due to insufficient efficacy data, according to FDA's Orthopedic and Rehabilitation Devices Panel

Purchase this Article

$35.00 Buy Now

For $35.00, purchase this 625-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

+ Show All | – Hide All

Offers & Events

Topics Covered in this Article

Click a keyword for related articles.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Q-Med's Durolane Knee Therapy Not Approvable - FDA Panel

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Health News Daily will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel